As young people age out of their pediatric or adolescent HIV care and treatment programs, they require different types of support. However, there is a lack of understanding and planning for potential transitions in care for young people in most countries. This Pediatric Transition Model was written to inform target-setting, forecasting, and planning for treatment and care programs for young people’s transitions in care.
The Pediatric HIV Transition Model can be applied in any PEPFAR-supported country to project the number of children, adolescents, and young adults on antiretroviral therapy (ART) who are eligible for transitions in care and switching to tenofovir/lamivudine/dolutegravir (TLD) or another newly-introduced regimen. This user’s guide provides step-by-step instruction for applying the Pediatric HIV Transition Model.